How to Help Your Patients Save Money on Spravato: A Provider's Guide to Savings Programs

For many patients with treatment-resistant depression (TRD), the clinical decision to prescribe Spravato is clear — but the financial reality can be a serious barrier to care. Without proactive cost management, patients face per-session costs of $600–$1,200 and first-month totals exceeding $8,200. As a provider, your practice's knowledge of Spravato savings programs can directly determine whether your patients can access treatment.

This guide covers the complete landscape of Spravato financial assistance available in 2026 — from manufacturer savings programs to insurance optimization strategies.

Spravato Cost Overview: The Provider's Perspective

Spravato costs are comprised of two distinct components that your patients (and your billing team) need to understand:

Medication cost: The esketamine drug itself, distributed through specialty pharmacy to your certified setting. This is what the Spravato withMe Savings Program and patient assistance programs address.

Clinic/administration cost: The cost of the clinical setting, monitoring staff time (2+ hours per session), and facility overhead. This varies widely between treatment centers and is a separate billing line — one that savings programs do not cover.

Spravato is typically billed under medical benefits (like a clinical procedure) rather than pharmacy benefits, which means it often involves Part B Medicare or medical insurance rather than pharmacy insurance. This distinction matters for prior authorization and billing workflows.

Program 1: Spravato withMe Savings Program (Commercially Insured Patients)

The Spravato withMe Savings Program is Janssen's co-pay assistance offering for commercially insured patients. Key details your practice should know:

Patient benefit: Eligible commercially insured patients pay as little as $10 per Spravato medication session

Maximum annual program benefit: $8,150 per calendar year

Eligibility: Commercially insured patients only — NOT available for Medicare, Medicaid, or TRICARE patients (federal program exclusion)

Enrollment: Typically handled at the certified treatment center during intake. Encourage your patients to confirm enrollment before their first session.

Clinical workflow recommendation: When referring a commercially insured patient to a certified Spravato treatment center, include a note in your referral specifically requesting that the center enroll the patient in the Spravato withMe program before the first session. This one step can reduce medication cost from hundreds of dollars to $10 per visit.

Program 2: Spravato withMe Patient Assistance Program (Uninsured/Underinsured)

For uninsured or underinsured patients who do not have commercial insurance, the Spravato withMe Patient Assistance Program may provide medication at no or significantly reduced cost based on income and eligibility criteria. As a provider:

Identify uninsured or high-OOP patients at the point of prescribing

Direct them to the patient assistance program through the Spravato withMe platform or by calling Janssen's patient support line

Consider involving your practice social worker or case manager to facilitate enrollment for complex social situations

Insurance Coverage: Optimizing the Prior Authorization Process

Proper prior authorization management directly impacts patient costs. Practices that submit complete, well-documented PA requests upfront have significantly higher first-pass approval rates. Standard documentation requirements across major commercial payers include:

DSM-5 TRD diagnosis with current MADRS or PHQ-9 scores

Documentation of 2+ failed antidepressant trials (drug, dose, duration, reason for discontinuation) in the current depressive episode

Prescribing psychiatrist credentials (many payers require psychiatrist involvement)

REMS-certified treatment facility confirmation

Absence of contraindications (severe hepatic impairment, aneurysmal vascular disease)

Initial PA approval duration is typically 12 months. Renewal requires demonstration of ongoing clinical response. Track PA expiration dates proactively — lapses in coverage can result in unexpected patient costs and treatment interruptions.

Medicare Patients: Part B vs. Part D Coverage

Medicare coverage for Spravato involves an important distinction that affects billing and patient costs:

Medicare Part B: Covers Spravato when administered in a REMS-certified healthcare facility, treating it as an outpatient medical procedure. Covers 80% of approved costs after the annual Part B deductible ($257 in 2025). Patient owes 20% coinsurance.

Medicare supplemental (Medigap) coverage: May cover the 20% Part B coinsurance. Encourage Medicare patients to check their supplemental coverage.

Medicare Advantage (Part C): Plans typically require prior authorization; coverage criteria vary by plan. Contact the specific Advantage plan to confirm coverage criteria before initiating treatment.

Important: The Spravato withMe Savings Program is NOT available to Medicare patients due to federal program exclusions. For Medicare patients, supplement coverage and minimizing the 20% coinsurance through Medigap is the key financial strategy.

Medicaid Patients: State-by-State Variability

Medicaid coverage for Spravato is available in most states but varies significantly:

Prior authorization is required in virtually all state Medicaid programs

Some states have specific quantity limits or session frequency caps

Copays for Medicaid patients are typically minimal or waived for covered services

Know your state's specific requirements — coverage criteria differ between fee-for-service Medicaid and managed Medicaid plans

Handling Insurance Denials: A Systematic Approach

Approximately 30% of initial PA denials are overturned on appeal. A systematic approach to denials can make the difference for your patients:

Request peer-to-peer review within 24–48 hours of denial. Direct physician-to-physician conversation is often the most effective appeal pathway.

Obtain the specific denial reason from the payer and address it directly in the appeal letter.

Supplement the appeal with updated clinical notes, a detailed letter of medical necessity, and citation of clinical trial data if relevant.

For commercial plans: Consider filing a complaint with your state insurance commissioner if the denial is for a covered indication and the patient meets all clinical criteria.

Practice Infrastructure: Building Efficient Spravato Financial Workflows

Practices that treat high volumes of Spravato patients benefit from dedicated workflows:

Designate a staff member as the Spravato PA coordinator — responsible for submission, follow-up, and renewal tracking

Create a patient financial screening checklist to identify insurance type, copay amounts, withMe eligibility, and PAP eligibility at intake

Build tracking systems for PA approval dates, renewal deadlines, and withMe enrollment status

Partner with your Janssen pharmaceutical representative for access to the most current program information and support resources

medfinder: Supporting Your Patients' Complete Medication Access

Your Spravato patients often also rely on oral medications — antidepressants, mood stabilizers, sleep aids — that can be difficult to find at local pharmacies. Medication gaps in supporting therapies can undermine the gains achieved through Spravato treatment. medfinder for providers calls pharmacies near your patients to find which ones have their prescriptions in stock — helping your patients stay on their full treatment plans without the frustration of calling pharmacies themselves.

For the patient-facing version of savings information, share: How to Save Money on Spravato in 2026: Coupons, Discounts, and Patient Assistance.